Literature DB >> 7437287

Organ-related and malignancy-associated reactivity of cancer patients' leucocytes: a leucocyte migration study with tumour and foetal extracts.

S Matzku, M Zöller, U Ikinger, M R Price.   

Abstract

Leucocytes from patients with a variety of tumours including gastric, colorectal, lung, kidney and mammary cancer, were tested in the leucocyte migration test (LMT) against organ-related and non-organ-related tumour and foetal extracts. The reactivity of cancer patients' leucocytes against a panel of organ-related tumour extracts was found to be 71-93%, depending on the tumour system tested. Cross-reactivity with a panel on non-organ-related tumour extracts was found in 0-38% of patients. Corresponding patterns of reactivity were obtained by testing patients' leucocytes against human foetal organ extracts; pathological migration indices (MI) were found in 70% of tests in which patients' leucocytes were reacted with organ-related extracts, and in 16% of tests with non-organ-related extracts. The data strongly support the concept that patients' leucocytes are sensitized to cross-reactive foetal determinants of organ-related specificities. Furthermore, it is proposed that foetal extracts as inducers of lymphokine production in presensitized lymphocytes could be used efficiently and reproducibly as a source of foetal antigen, as well as in the clinical application of the LMT procedure.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437287      PMCID: PMC2010430          DOI: 10.1038/bjc.1980.274

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Anti-tumour antibodies in normal mouse sera.

Authors:  S E Martin; W J Martin
Journal:  Int J Cancer       Date:  1975-04-15       Impact factor: 7.396

2.  Migration enhancement factor: a new lymphokine.

Authors:  R H Weisbart; R Bluestone; L S Goldberg; C M Pearson
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

3.  Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture.

Authors:  E T Bloom
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

4.  Demonstration of tumor-associated delayed cutaneous hypersensitivity reactions in patients with lung cancer and in pateients with carcinoma of the cervix.

Authors:  S A Wells; J F Burdick; C Christiansen; A S Ketcham; P C Adkins
Journal:  Natl Cancer Inst Monogr       Date:  1973-06

5.  Biological and chemical characterization of human histocompatibility antigens.

Authors:  R A Reisfeld; B D Kahan
Journal:  Fed Proc       Date:  1970 Nov-Dec

6.  Circulating antibodies and leucocyte migration inhibition to colon-associated antigen in ulcerative colitis and Crohn's disease.

Authors:  H Marcussen; G Bendixen
Journal:  Scand J Gastroenterol       Date:  1974       Impact factor: 2.423

7.  Immunological studies with human neoplasms.

Authors:  D L Morton
Journal:  J Reticuloendothel Soc       Date:  1971-07

8.  Natural antibodies directed against murine lymphosarcoma cells: variability of level in individual mice.

Authors:  M A Pierotti; M I Colnaghi
Journal:  Int J Cancer       Date:  1976-08-15       Impact factor: 7.396

9.  Cellular hypersensitivity of gp55 of RIII-murine mammary tumor virus and gp55-like protein of human breast cancers.

Authors:  M M Black; R E Zachrau; A S Dion; B Shore; D L Fine; H P Leis; C J Williams
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

10.  Tumour antigenicity in ovarian cancer.

Authors:  L Levin; J E McHardy; O M Curling; C N Hudson
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

View more
  2 in total

1.  Expression by human fetal organs of organ-specific cancer neoantigens as measured by leukocyte adherence inhibition.

Authors:  M Gubersky; D M Thomson; M Lajzerowicz
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Reaction of the leukocytes of melanoma patients and control donors, including pregnant women, with melanoma- and fetus-derived materials.

Authors:  A J Cochran; G Todd; D M Hart; L J Morrison; R M MacKie
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.